Which undervalued stocks are in the weight loss drug sector

After my careful screening, there are currently **5** undervalued stocks in the weight loss drug sector. The details are as follows: |code|stock code|stock name|last-price|last-change|Theme|Theme Description|Inclusion Reason|Market Cap[20240808]|Free Cash Flow[20240630]|Total Revenue year-on-year growth rate[20240630]|market_code| |---|---|---|---|---|---|---|---|---|---|---|---| |LLY|LLY.N|Eli Lilly|845.31|9.476260781723518|Weight-Loss Treatment|Weight-loss treatment is medicine that has the effect of losing weight. Weight loss treatment currently in clinical use including glucagon-like peptide-1 (GLP-1), orlistat, lorcaserin, qsymia, phentermine, liraglutide and etc.|From Yahoo Finance: Eli Lilly's stock has surged by approximately 70% this year. This multinational pharmaceutical company, based in the United States, attributes its growth partly to securing U.S. FDA approval for the diabetes/obesity drug Mounjaro (Tirzepatide), which targets obesity-related hormones GLP-1 and GIP. One of the Wall Street analysts upgraded the potential peak sales target for Mounjaro to a whopping $68.7 billion. Beyond the obesity drugs, Eli Lilly has more potential blockbuster drugs in its pipeline. For example, the company expects the U.S. FDA decision for its Alzheimer’s treatment - Donanemab - later this year. If approved, the drug could garner $5 billion in peak sales.|8.0340441440118E11|3.1472997643E9|35.98007723679936|169| |NVO|NVO.N|Novo Nordisk|128.17|7.498112891050896|Weight-Loss Treatment|Weight-loss treatment is medicine that has the effect of losing weight. Weight loss treatment currently in clinical use including glucagon-like peptide-1 (GLP-1), orlistat, lorcaserin, qsymia, phentermine, liraglutide and etc.|From Nasdaq：Novo Nordisk A/S, a global healthcare company, specializes in pharmaceutical research, development, manufacturing, and marketing. Notably, their recent guidance update for operating profit growth is significant, with a revised forecast of 40% to 46%, surpassing the prior estimate of 31% to 37%. The key drivers of this positive change are Wegovy and Ozempic, both based on the semaglutide molecule.|5.7068552315628E11|3.8395679555354E9|22.77346479303364|169| |AZN|AZN.O|Astrazeneca|81.85|1.5256760109153928|Weight-Loss Treatment|Weight-loss treatment is medicine that has the effect of losing weight. Weight loss treatment currently in clinical use including glucagon-like peptide-1 (GLP-1), orlistat, lorcaserin, qsymia, phentermine, liraglutide and etc.|From Bloomberg, June 13, 2023: AstraZeneca has already made a foray into obesity medicines, announcing a partnership with Regeneron Pharmaceuticals Inc. in 2021. The firms were looking to develop small molecule modulators against GPR75, after rare mutations in individuals with at least one inactive copy of the gene were found to face a 54% lower risk of obesity.|2.537803450637E11|4.515843952E9|13.332165381920111|185| |GSK|GSK.N|GSK|40.02|1.6510033020066186|Weight-Loss Treatment|Weight-loss treatment is medicine that has the effect of losing weight. Weight loss treatment currently in clinical use including glucagon-like peptide-1 (GLP-1), orlistat, lorcaserin, qsymia, phentermine, liraglutide and etc.|From Officials Web: GSK has announced that alli – the first clinically proven over the counter weight loss aid – is available in pharmacies across Europe. Clinical trials show that alli, when used in conjunction with a reduced calorie, lower-fat diet, can help people lose 50 per cent more weight than by dieting alone. So for every two kilos (pounds) lost by dieting alone, alli could help them lose one more. It works by stopping some of the fat you eat being absorbed into the body and turning into extra kilos (pounds).|8.294261076009E10|4.584101814592E9|9.23928674885258|169| |SNY|SNY.O|Sanofi|52.11|0.5984555984556029|Weight-Loss Treatment|Weight-loss treatment is medicine that has the effect of losing weight. Weight loss treatment currently in clinical use including glucagon-like peptide-1 (GLP-1), orlistat, lorcaserin, qsymia, phentermine, liraglutide and etc.|From Officials Web: Sanofi Aventis are an innovative global healthcare company. This company has an obesity drug called Semaglutide. Semaglutide is approved for weight management and is sold under the brand name Wegovy. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps people with obesity lose weight when used in combination with diet and exercise. It has shown significant effectiveness in clinical trials and is considered a promising treatment for obesity.|1.3198032643032E11|7.9981144646314E9|4.495375123534644|185|